Why the study?
To explore whether small extracellular vesicles derived from young adipose-derived stem cells can reverse age-associated structural, molecular, and functional cardiac changes.
Does intravenous administration of small extracellular vesicles from young adipose-derived stem cells ameliorate age-related structural, molecular, and functional changes in the hearts of old mice?
Does intravenous administration of small extracellular vesicles from young adipose-derived stem cells ameliorate age-related structural, molecular, and functional changes in the hearts of old mice?
Small extracellular vesicles from young adipose-derived stem cells represent a promising noninvasive strategy to mitigate age-related cardiac structural and functional decline.
Answers are grounded in this paper and cite their sources.
Should not yet change practice for age-related diastolic dysfunction; leaves open human translation of ADSC-sEVs.
BACKGROUND: Aging entails a progressive decline in physiological functions, elevating the risk of age-related diseases like heart failure or aortic stenosis. Stem cell therapies, especially those that use paracrine signaling, can potentially mitigate the adverse effects of aging. OBJECTIVES: The objective is to explore the potential of small extracellular vesicles (sEVs) derived from young adipose-derived stem cells (ADSC-sEVs) in reversing structural, molecular, and functional changes associated with aging in the heart. METHODS: Aged C57BL/6J mice were treated intravenously with ADSC-sEVs from young mice or PBS as controls. Young mice were included to identify specific age-associated changes. The impact of sEV treatment on cardiac function was assessed using transthoracic echocardiography and physical endurance tests. Histological and molecular analyses were conducted on heart tissue to evaluate structural changes and markers of senescence, inflammation, and oxidative stress. A comprehensive metabolomic analysis was also performed on heart tissues to identify changes in metabolic profiles associated with aging and treatment status. RESULTS: The administration of ADSC-sEVs significantly improves several aging-associated cardiac parameters, including oxidative stress, inflammation, and cellular senescence reductions. We also report on the age-related reversal of myocardial structure and function changes, highlighted by decreased fibrosis and improved vascularization. Notably, echocardiographic assessments reveal that sEV treatments ameliorate diastolic dysfunction and left ventricle structural alterations typically associated with aging. Furthermore, the treatment shifts the heart metabolome towards a more youthful profile. CONCLUSIONS: These results denote the potential of ADSC-sEVs as a novel, noninvasive therapeutic strategy for mitigating cardiac aging-associated functional decline.
No takes yet. Share an insight, caveat, or question.
Sanz‐Ros et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: